Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2025-A00880-49 | Other Identifier | ANSM |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study aims at defining the role of ferroptosis s in the physiopathology of systemic lupus erythematosus (SLE). Ferroptosis (phenomenon of cellular death regulated by iron) is a metabolic pathway potentially implicated in SLE with potential for the discovery of new therapeutic strategies.
Systemic lupus erythematosus (SLE) is a complex autoimmune disease affecting various organs. Regulatory T cells (Treg) and platelets play a crucial role in the pathogenesis of SLE by regulating immunity and promoting inflammation. Ferroptosis, an iron-regulated cell death process, is emerging as a key player in many diseases, including SLE.
The project, FERROLUP, aims to understand the role of ferroptosis in SLE and to explore the therapeutic potential of selenium compounds to modulate this process. Recent work has identified down-regulation of glutathione peroxidase 4 (GPx4) by immune complexes and interferon-alpha in neutrophils, leading to ferroptosis and worsening of SLE. In addition, data suggest the involvement of ferroptosis in lupus nephritis.
The Bordeaux team has developed selenium compounds, GPx4 mimics, capable of inhibiting ferroptosis in lupus neutrophils. These compounds have shown promising efficacy in mouse models and preliminary human studies in another inflammatory disease. The FERROLUP project aims to characterize the level of lipid peroxidation and GPx4 expression in SLE patients, and to test the impact of selenium compounds on the inhibition of ferroptosis induced by P-selectin, a molecule involved in Treg dysfunction.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Systemic lupus erythematosus (SLE) | Experimental |
| |
| Rheumatoid arthritis or an inflammatory bowel | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| blood sample | Biological | 30 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation |
|
| Measure | Description | Time Frame |
|---|---|---|
| Measurement of lipid peroxidation in regulatory T lymphocytes population in lupus subjects. | At baseline (Day 0) |
| Measure | Description | Time Frame |
|---|---|---|
| Measurement of lipid peroxidation in regulatory T lymphocytes population in lupus subjects and controls. | At baseline (Day 0) | |
| Measurement of lipid peroxidation in other immune cells (T and B lymphocyte populations) in lupus subjects and controls | At baseline (Day 0) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Christophe RICHEZ, Prof | Contact | (0)5 56 79 55 56 | +33 | christophe.richez@chu-bordeaux.fr |
| Thomas BARNETCHE, PhD | Contact | (0)5.57.82.04.93 | +33 | thomas.barnetche@chu-bordeaux.fr |
| Name | Affiliation | Role |
|---|---|---|
| Christophe RICHEZ, Prof | University Hospital, Bordeaux | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU de Bordeaux - service de rhumatologie | Recruiting | Bordeaux | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008180 | Lupus Erythematosus, Systemic |
| D001327 | Autoimmune Diseases |
| ID | Term |
|---|---|
| D003240 | Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D001800 | Blood Specimen Collection |
| ID | Term |
|---|---|
| D013048 | Specimen Handling |
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| GPX4 expression in lupus subjects and controls. | At baseline (Day 0) |
| Correlation between ferroptosis markers and the level of activity in B lymphocyte populations | At baseline (Day 0) |
| In-vitro effect of BXT on different T lymphocytes population in the presence of P-selectin in sera of lupus subjects and controls | At baseline (Day 0) |
| D011677 | Punctures |
| D013514 | Surgical Procedures, Operative |
| D008919 | Investigative Techniques |